Loading...
Docoh

DaVita (DVA)

DaVita Inc. is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is one of the largest providers of kidney care services in the U.S. and has been a leader in clinical quality and innovation for more than 20 years. Through DaVita Kidney Care, the company treats patients with chronic kidney failure and end stage kidney disease. DaVita is committed to bold, patient-centric care models, implementing the latest technologies and moving toward integrated care offerings for all. Through these efforts, DaVita has also become the largest provider of home dialysis in the country. As of December 31, 2020, DaVita served 204,200 patients at 2,816 outpatient dialysis centers in the United States. The company also operated 321 outpatient dialysis centers in ten countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere.

Company profile

Ticker
DVA
Exchange
Website
CEO
Javier Rodriguez
Employees
Incorporated
Location
Fiscal year end
Former names
DAVITA HEALTHCARE PARTNERS INC., DAVITA INC, TOTAL RENAL CARE HOLDINGS INC
SEC CIK
Subsidiaries
Aberdeen Dialysis, LLC • Accountable Kidney Care, LLC • Ahern Dialysis, LLC • AI Care Insights, LLC • Alenes Dialysis, LLC • American Fork Dialysis, LLC • American Medical Insurance, Inc. • Amity Dialysis, LLC • Animas Dialysis, LLC • Arcadia Gardens Dialysis, LLC ...
IRS number
510354549

DVA stock data

Analyst ratings and price targets

Last 3 months

Calendar

1 Aug 22
12 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 355.74M 355.74M 355.74M 355.74M 355.74M 355.74M
Cash burn (monthly) 21.61M 70.9M (no burn) (no burn) (no burn) (no burn)
Cash used (since last report) 31.31M 102.7M n/a n/a n/a n/a
Cash remaining 324.43M 253.04M n/a n/a n/a n/a
Runway (months of cash) 15.0 3.6 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
23 Jun 22 Staffieri Michael David Common Stock Buy Acquire P No No 77.7 20,000 1.55M 61,190
6 Jun 22 Rodriguez Javier Common Stock Payment of exercise Dispose F No No 96.7 11,326 1.1M 315,622
6 Jun 22 Rodriguez Javier Common Stock Sale back to company Dispose D No No 96.7 54,111 5.23M 326,948
6 Jun 22 Rodriguez Javier Common Stock Option exercise Acquire M No No 65.48 79,909 5.23M 381,059
6 Jun 22 Rodriguez Javier Stock Appreciation Rights Common Stock Option exercise Dispose M No No 65.48 79,909 5.23M 0
6 Jun 22 Waters Kathleen Alyce Common Stock Payment of exercise Dispose F No No 96.7 3,636 351.6K 69,284
6 Jun 22 Waters Kathleen Alyce Common Stock Sale back to company Dispose D No No 96.7 14,172 1.37M 72,920
6 Jun 22 Waters Kathleen Alyce Common Stock Option exercise Acquire M No No 65.48 20,929 1.37M 87,092
6 Jun 22 Waters Kathleen Alyce Stock Appreciation Rights Common Stock Option exercise Dispose M No No 65.48 20,929 1.37M 0
3 Jun 22 Desoer Barbara J Common Stock Sell Dispose S No No 97.418 2,320 226.01K 0
88.0% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 502 483 +3.9%
Opened positions 61 77 -20.8%
Closed positions 42 88 -52.3%
Increased positions 138 126 +9.5%
Reduced positions 208 205 +1.5%
13F shares Current Prev Q Change
Total value 10.58B 11.05B -4.2%
Total shares 80.32M 84.11M -4.5%
Total puts 932.8K 845.7K +10.3%
Total calls 765.5K 748.4K +2.3%
Total put/call ratio 1.2 1.1 +7.8%
Largest owners Shares Value Change
BRK.A Berkshire Hathaway 36.1M $4.08B 0.0%
Vanguard 7.22M $817.08M -3.4%
BLK Blackrock 5.34M $603.81M -5.6%
STT State Street 2.89M $327.19M -5.9%
LSV Asset Management 2.26M $255.11M -2.4%
Dimensional Fund Advisors 1.44M $163.24M -14.7%
IVZ Invesco 1.33M $150.11M -11.7%
Gates Capital Management 1.28M $144.22M -20.4%
Geode Capital Management 1.18M $133.13M -0.5%
NTRS Northern Trust 744.29K $84.19M -6.5%
Largest transactions Shares Bought/sold Change
Norges Bank 0 -1.21M EXIT
DPM Capital 0 -691.43K EXIT
Citadel Advisors 71.66K -525.54K -88.0%
Iron Triangle Partners 0 -450K EXIT
Glenview Capital Management 129.1K -403.54K -75.8%
Park West Asset Management 557.13K +394.3K +242.1%
Schroder Investment Management 349.45K +329.06K +1613.6%
Gates Capital Management 1.28M -326.41K -20.4%
BLK Blackrock 5.34M -316.69K -5.6%
Vanguard 7.22M -257.22K -3.4%

Financial report summary

?
Risks
  • Risks Related to the Operation of our Business
  • We face various risks related to the dynamic and evolving novel coronavirus pandemic, many of which may have a material adverse impact on us.
  • Our business is subject to a complex set of governmental laws, regulations and other requirements and any failure to adhere to those requirements, or any changes in those requirements, could have a material adverse effect on our business, results of operations, financial condition and cash flows, could materially harm our stock price, and in some circumstances, could materially harm our reputation.
  • Changes in federal and state healthcare legislation or regulations could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • If the number or percentage of patients with higher-paying commercial insurance declines, if the average rates that commercial payors pay us decline, if patients in commercial plans are subject to restriction in plan designs, if we are unable to maintain contracts with payors with competitive terms, including, without limitation, reimbursement rates, scope and duration of coverage and in-network benefits, it could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • If we are not able to successfully implement our strategy with respect to home-based dialysis, including maintaining our existing business and further developing our capabilities in a complex and highly regulated environment, it could have a material adverse effect on our business, results of operations, financial condition and cash flows, and could materially harm our reputation.
  • Changes in the structure of and payment rates under the Medicare ESRD program or changes in state Medicaid or other non-Medicare government-based programs or payment rates could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • Our business is labor intensive and if our labor costs continue to rise, including due to shortages, changes in certification requirements and/or higher than normal turnover rates in skilled clinical personnel; or currently pending or future governmental laws, rules, regulations or initiatives impose additional requirements or limitations on our operations or profitability; or, if we are unable to attract and retain employees; or if union organizing activities or legislative or other changes result in significant increases in our operating costs or decreases in productivity, we may experience disruptions in our business operations and increases in operating expenses, among other things, any of which could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.
  • Privacy and information security laws are complex, and if we fail to comply with applicable laws, regulations and standards, including with respect to third-party service providers that utilize sensitive personal information on our behalf, or if we fail to properly maintain the integrity of our data, protect our proprietary rights to our systems or defend against cybersecurity attacks, we may be subject to government or private actions due to privacy and security breaches or suffer losses to our data and information technology assets, any of which could have a material adverse effect on our business, results of operations, financial condition and cash flows or materially harm our reputation.
  • If certain of our suppliers do not meet our needs, if there are material price increases on supplies, if we are not reimbursed or adequately reimbursed for drugs we purchase or if we are unable to effectively access new technology or superior products, it could negatively impact our ability to effectively provide the services we offer and could have a material adverse effect on our business, results of operations, financial condition, cash flows and could materially harm our reputation.
  • Changes in clinical practices, payment rates or regulations impacting pharmaceuticals could have a material adverse effect on our business, results of operations, financial condition, and cash flows and negatively impact our ability to care for patients.
  • If we are unable to compete successfully, including, without limitation, implementing our growth strategy and/or retaining patients and developing and maintaining relationships with physicians and hospitals, it could materially adversely affect our business, results of operations, financial condition and cash flows.
  • The U.S. ancillary services and strategic initiatives and international operations that we operate or invest in now or in the future may generate losses and may ultimately be unsuccessful. In the event that one or more of these activities is unsuccessful, our business, results of operations, financial condition and cash flows may be negatively impacted and we may have to write off our investment and incur other exit costs.
  • Expansion of our operations to and offering our services in markets outside of the U.S. subjects us to political, economic, legal, operational and other risks that could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.
  • Failing to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely, including, without limitation, our clinical, billing and collections systems, or failure to adhere to federal and state data sharing and access requirements and regulations could materially adversely affect our business, results of operations, financial condition, cash flows and reputation.
  • We may engage in acquisitions, mergers, joint ventures or dispositions, which may materially affect our results of operations, debt-to-capital ratio, capital expenditures or other aspects of our business, and, under certain circumstances, could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.
  • If our joint ventures were found to violate the law, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.
  • Our aspirations, goals and disclosures related to environmental, social and governance (ESG) matters expose us to numerous risks, including without limitation risks to our reputation and stock price.
  • The level of our current and future debt could have an adverse impact on our business, and our ability to generate cash to service our indebtedness and for other intended purposes and our ability to maintain compliance with debt covenants depends on many factors beyond our control.
  • We could be subject to adverse changes in tax laws, regulations and interpretations or challenges to our tax positions.
  • Deterioration in economic conditions, general inflationary pressures, disruptions in the financial markets or the effects of natural or other disasters, political instability, public health crises or adverse weather events such as hurricanes, earthquakes, fires or flooding could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • We may be subject to liability claims for damages and other expenses that are not covered by insurance or exceed our existing insurance coverage that could have a material adverse effect on our business, results of operations, financial condition, cash flows and could materially harm our reputation.
  • If we fail to successfully maintain an effective internal control over financial reporting, the integrity of our financial reporting could be compromised, which could have a material adverse effect on our ability to accurately report our financial results, the market's perception of our business and our stock price.
  • Provisions in our organizational documents, our compensation programs and policies and certain requirements under Delaware law may deter changes of control and may make it more difficult for our stockholders to change the composition of our Board of Directors and take other corporate actions that our stockholders would otherwise determine to be in their best interests.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: ACA, achieve, achieved, added, adequacy, agency, aggressively, arbitrary, attempt, attempting, begun, behavior, breadth, broadened, burden, Century, commencement, deciding, device, discourage, disproportionate, disproportionately, drawn, education, family, half, highest, influenced, interpret, Irrespective, job, launch, legacy, MA, machine, macroeconomic, manner, Medtronic, member, monkeypox, MSPA, NewCo, nonacute, objective, Payer, publish, readable, refusing, reinstatement, rely, remanded, removal, renegotiated, reversed, successful, transparency, unable, underinsured, uniformly
Removed: alleged, cooperating, count, defendant, elevated, ESCO, fourth, hand, led, nondeductible, undrawn, unrealized, violation